Compare NC & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | PEPG |
|---|---|---|
| Founded | 1913 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.1M | 353.9M |
| IPO Year | 2006 | 2022 |
| Metric | NC | PEPG |
|---|---|---|
| Price | $51.12 | $4.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 11.5K | ★ 660.7K |
| Earning Date | 03-04-2026 | 03-04-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $104,778,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.00 | $0.89 |
| 52 Week High | $59.42 | $7.80 |
| Indicator | NC | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 38.67 |
| Support Level | $45.41 | $4.36 |
| Resistance Level | $55.09 | $5.50 |
| Average True Range (ATR) | 2.76 | 0.51 |
| MACD | -0.46 | -0.16 |
| Stochastic Oscillator | 31.68 | 12.94 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.